quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:01:15·15d
PRRelease
Ascendis Pharma A/S logo

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia

ASND· Ascendis Pharma A/S
Health Care
Original source

Companies

  • ASND
    Ascendis Pharma A/S
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies-
  • Jan 28UpdateBarclays$342.00
  • Nov 18UpdateWolfe Research$255.00
  • Oct 17UpdateRaymond James$271.00
  • Jul 3UpdateMorgan Stanley$250.00
  • May 5UpdateMorgan Stanley$250.00

Related

  • SEC2d
    SEC Form 6-K filed by Ascendis Pharma A/S
  • PR2d
    Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
  • SEC2d
    SEC Form 6-K filed by Ascendis Pharma A/S
  • SEC3d
    Amendment: SEC Form 8-A12B/A filed by Ascendis Pharma A/S
  • SEC3d
    SEC Form 6-K filed by Ascendis Pharma A/S
  • PR3d
    Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
  • SEC15d
    SEC Form 6-K filed by Ascendis Pharma A/S
  • SEC15d
    SEC Form 6-K filed by Ascendis Pharma A/S
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022